Cargando…

Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection

The bismuth-based quadruple regimen has been applied in Helicobacter pylori rescue therapy worldwide. The non-bismuth-based quadruple therapy or “concomitant therapy” is an alternative option in first-line eradication but has not been used in second-line therapy. Discovering a valid regimen for resc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jheng, Guang-Hong, Wu, I-Chen, Shih, Hsiang-Yao, Wu, Meng-Chieh, Kuo, Fu-Chen, Hu, Huang-Ming, Liu, Chung-Jung, Hsu, Wen-Hung, Hu, Chi-Tan, Bair, Ming-Jong, Kuo, Chao-Hung, Wu, Deng-Chyang, Hsu, Ping-I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450213/ https://www.ncbi.nlm.nih.gov/pubmed/26090383 http://dx.doi.org/10.1155/2015/163960

Ejemplares similares

Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice
por: Hung, Kuo-Tung, et al.
Publicado: (2021)

The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance
por: Huang, Tzu-Hsin, et al.
Publicado: (2021)

A comparison between dexlansoprazole modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial
por: Tai, Wei-Chen, et al.
Publicado: (2019)

Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori
por: Wu, Meng-Chieh, et al.
Publicado: (2017)

Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes
por: Kim, Sung Eun, et al.
Publicado: (2017)

Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections
por: Yang, Tiankuo, et al.
Publicado: (2020)

The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012
por: Kuo, Chao-Hung, et al.
Publicado: (2012)

The Effect of Helicobacter pylori Eradication on the Levels of Essential Trace Elements
por: Wu, Meng-Chieh, et al.
Publicado: (2014)

A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection
por: Wu, Deng-Chyang, et al.
Publicado: (2016)

Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
por: Gisbert, Javier P, et al.
Publicado: (2012)

Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection
por: Kim, Jeemyoung, et al.
Publicado: (2022)

Comparison between Single-Dose Esomeprazole- and Pantoprazole-Based Triple Therapy on the Effectiveness for Helicobacter pylori Eradication in Taiwanese Population
por: Shih, Hsiang-Yao, et al.
Publicado: (2012)

Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth
por: Niu, Zhan-Yue, et al.
Publicado: (2021)

Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication
por: Huang, Hsiang Tso, et al.
Publicado: (2018)

Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-Line Helicobacter pylori Eradication
por: Tai, Wei-Chen, et al.
Publicado: (2015)

A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice
por: Kuo, Chao-Hung, et al.
Publicado: (2016)

Multiple Bismuth Quadruple Therapy Containing Tetracyclines Combined with Other Antibiotics and Helicobacter pylori Eradication Therapy
por: Sun, Yingchao, et al.
Publicado: (2022)

Levofloxacin-containing triple therapy versus bismuth-based quadruple therapy as regimens for second line anti- Helicobacter pylori
por: Seyyedmajidi, Mohamadreza, et al.
Publicado: (2019)

Empiric “Three-in-One” Bismuth Quadruple Therapy for Second-Line Helicobacter pylori Eradication: An Intervention Study in Southern Italy
por: Losurdo, Giuseppe, et al.
Publicado: (2022)

The Comparison of Levofloxacin- and Clarithromycin-Based Bismuth Quadruple Therapy Regimens in Helicobacter pylori Eradication
por: Arj, Abbas, et al.
Publicado: (2020)

The Effect of Quadruple Therapy with Polaprezinc or Bismuth on Gut Microbiota after Helicobacter pylori Eradication: A Randomized Controlled Trial
por: Wu, Dingkun, et al.
Publicado: (2022)

Helicobacter pylori Infection and Anemia in Taiwanese Adults
por: Shih, Hsiang-Yao, et al.
Publicado: (2013)

Second-Line Bismuth-Containing Quadruple Therapy for Helicobacter pylori Infection: A 12-Year Study of Annual Eradication Rates
por: Shin, Kiwon, et al.
Publicado: (2021)

Efficacy of a bismuth-based quadruple therapy regimen for Helicobacter pylori eradication in Saudi Arabia
por: Alsohaibani, Fahad, et al.
Publicado: (2020)

Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori
por: Zhang, Lingyun, et al.
Publicado: (2019)

Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori
por: Wang, Junxian, et al.
Publicado: (2021)

The efficacy and safety of furazolidone-bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotic supplementation
por: Noorbakhsh, Nafeh, et al.
Publicado: (2022)

Bismuth-Based Quadruple Therapy for Clarithromycin-Resistant Helicobacter pylori Infection: Effectiveness and Cost-Efficiency
por: Lee, Moon Won, et al.
Publicado: (2022)

Helicobacter pylori Infection
por: Hsu, Ping-I, et al.
Publicado: (2015)

Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori
por: Niu, Min, et al.
Publicado: (2022)

Helicobacter pylori Infection-Induced Hepatoma-Derived Growth Factor Regulates the Differentiation of Human Mesenchymal Stem Cells to Myofibroblast-Like Cells
por: Liu, Chung-Jung, et al.
Publicado: (2018)

Rescue therapy for refractory Helicobacter pylori infection: current status and future concepts
por: Wang, Song-Wei, et al.
Publicado: (2023)

The Association of Helicobacter pylori Eradication with the Occurrences of Chronic Kidney Diseases in Patients with Peptic Ulcer Diseases
por: Wang, Jiunn-Wei, et al.
Publicado: (2016)

Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice
por: Shaikh, Tahir, et al.
Publicado: (2016)

Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan
por: Liang, Chih-Ming, et al.
Publicado: (2020)

Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed Helicobacter pylori Infection as 14 Days of Bismuth-Based Quadruple Therapy
por: Moon, Sang-Gon, et al.
Publicado: (2022)

Corrigendum to “Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori”
por: Zhang, Lingyun, et al.
Publicado: (2021)

Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication
por: Huh, Ki Young, et al.
Publicado: (2021)

Optimal treatment duration of bismuth-containing quadruple therapy in Helicobacter pylori infection: A retrospective study
por: Kim, Ji Yoon, et al.
Publicado: (2023)

Helicobacter pylori and Systemic Disease
por: Kuo, Chao-Hung, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_idkqtkmlmu0056anf0ggvdja8d